Reviva Pharmaceuticals Announces 1-for-20 Reverse Stock Split to Avoid Nasdaq Delisting
Summary
Reviva Pharmaceuticals will implement a 1-for-20 reverse stock split on March 9, 2026, to address its Nasdaq minimum bid price deficiency and avoid delisting by the March 27, 2026 deadline.
Key Events
-
1-for-20 Reverse Stock Split Approved
The company filed a Certificate of Amendment to its charter, effecting a one-for-twenty (1:20) reverse stock split of its common stock, effective March 9, 2026. Fractional shares will be rounded up to the nearest whole share.
-
Nasdaq Delisting Threat Imminent
Reviva Pharmaceuticals received a Nasdaq notice in May 2025 for failing to maintain a minimum bid price of $1.00. After a hearing, Nasdaq granted an exception to demonstrate compliance by March 27, 2026.
-
Split Aims for Nasdaq Compliance
The reverse stock split is intended to increase the per-share price to meet Nasdaq's $1.00 minimum bid price requirement, which is crucial for the company's continued listing on the exchange.
-
Company Warns of Potential Negative Impacts
The company cautioned that the reverse split may not lead to a proportionate increase in stock price, sustained price levels, or maintained liquidity, and could result in a lower total market capitalization.
Analysis
Reviva Pharmaceuticals Holdings, Inc. has enacted a 1-for-20 reverse stock split, effective March 9, 2026, as a critical measure to regain compliance with Nasdaq's minimum bid price requirement. The company has been non-compliant since May 2025 and faces a delisting deadline of March 27, 2026. While the reverse split aims to increase the per-share price above $1.00, the company explicitly warns that it cannot guarantee a proportionate price increase, sustained market price, or maintained liquidity, and that total market capitalization could decrease. This move highlights significant financial distress and the urgent need to maintain its exchange listing, which is vital for capital access and investor confidence.
At the time of this filing, RVPH was trading at $0.25 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $28.1M. The 52-week trading range was $0.20 to $1.35. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.